Frankincense

Frankincense or boswellia resin is the resin of the frankincense tree.

Indian frankincense is of medicinal interest. The resin of this frankincense solidifies into yellowish to brownish lumps.

The boswellic acids and tirucallic acids in the resin extracts are of pharmacological importance. One mechanism of action of boswellic acids, especially acetyl-keto-boswellic acid (AKBA), is the direct inhibition of 5-lipoxygenase (Safayhi H et al. 1992). The 5-lipoxygenase is a key enzyme for the biosynthesis of leukotrienes. Further pharmacological effects of frankincense are based on the proven inhibition of topoisomerases (Wang L-G et al.1991, Hoernlein RF et al.1999) and inhibition of leukocyte elastase (Safayhi H et al. 1997). Leukotrienes play a key role in many allergic and inflammatory diseases. 5 Lipoxygenase is the key enzyme in the synthesis of leukotrienes.

It is used in the perfume industry, in cosmetic products s. Boswellia serrata extract (INCI) and in pharmaceuticals.

Frankincense essential oil is obtained from the resin by steam distillation.

The main constituents of the resin are monoterpenes, sesquiterpenes, monoterpenols, sesquiterpenols (see terpenes below) and ketones. Other ingredients are various boswellic acids and incensol. Indian frankincense is used phytotherapeutically, see Boswellia serrata Roxb. There is no monograph on this from the HMPC. However, there is a positive ESCOP monograph on the indication: "painful joint arthritis, inflammatory bowel diseases".

On December 11, 2002, the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) in London published a positive opinion on the use of Boswellia serrata resin extract from Pharmasan GmbH, Freiburg. This includes a Europe-wide approval of Boswellia serrata resin extract for the treatment of perifocal edema caused by brain tumors (EMEA 2002).

The inhibition of leukotriene synthesis defines the use of Boswellia serrata extract for allergic and inflammatory diseases with leukotriene activation.

In classical European naturopathy, frankincense is mainly used and clinically investigated in rheumatology, gastroenterology, pulmonology and neurology.

Rheumatology: There are contradictory study results for rheumatoid arthritis. On the one hand, there are significant improvements (Etzel R et al. 1996) and on the other hand no influence at all on inflammation values and subjective perception (Sander O et al. 1998).

Gastroenterology: There are studies on both ulcerative colitis (Grupta I. et al. 1997 and 2001) and Crohn's disease (Gerhard H et al. 2001) which have shown a comparable effect of Boswellia serrata extracts and sulfasalazine.

Pulmonology: There are indications of a clear improvement with Boswellia serrata extracts, although the study involved a very small number of 40 patients (Gupta I et al. 1998).

Neurology: There are indications of an influence on perifocal edema in gliomas and astrocytomas (Heldt MR et al. 1998).

Incensol, another ingredient of frankincense resin, showed anxiolytic and antidepressant effects in animal models. An antidepressant effect of incensol has not yet been proven in humans.

Some studies suggest that olibanum may improve memory performance in part by regulating the levels of the transcription factors CREB-1 and CREB-2 (cAMP response element-binding) via positive/negative feedback loops (Jebelli A et al. 2019).

In addition, boswellic acids have been shown to have antiproliferative effects on various tumor cell lines (e.g. malignant melanoma, glioblastoma, liver carcinoma) in vitro, which are based on an induction of apoptosis.

Frankincense is traditionally used as an anti-inflammatory and antibacterial agent. In East Africa, for example, it is used against diseases such as syphilis, schistosomiasis and stomach ailments.

Boswellia serrata extract H15® (Pharmasan GmbH Freiburg), H 15 Ayurmedica® capsules, Trisana® Dermal C, boswellia-Loges® frankincense capsules

1. Ammon H P (2002) Boswellic acids (ingredients of frankincense) as effective principles for the treatment of chronic inflammatory diseases. Wiener Medizinische Wochenschrift 152: 373-378.
2. Bertsche T el al. (2002) Therapy with frankincense extracts. Pharmazeutische Zeitung 51.
3. Etzel R (1996) Special extract of Boswellia serrata (H15) in the treatment of rheumatoid arthritis. Phytomed 3: 91 - 94.
4. Gerhard H et al. (2001) Therapy of active Crohn's disease with Boswellia serrata extract H15. Z Gastroenterol 39: 11 - 17.
5. Gilbert NC et al. (2020) Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products, Nature Chemical Biology volume 16: 783-790.
6. Gupta I et al.(1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2: 3743.
7. Gupta I et al. (1998) Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 3: 511 - 514.
8. Gupta I et al. (2001) Effects of Boswellia serrata gum resin in patients with chronic colitis. Planta Med 67: 391 - 395.
9. Heldt MR et al. (1997) Boswellic acids exhibit cytotoxic effects on brain tumor cells independent from 5-lipoxygenase inhibition. Naunyn Schmiedeberg's Arch Pharmacol 355: 30
10. Hoernlein RF et al. (1999) Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J. Pharmacol Exp Ther 288: 613 - 619.
11. Jebelli A et al. (2019) Beta-Boswellic Acid and Ethanolic Extract of Olibanum Regulating the Expression Levels of CREB-1 and CREB-2 Genes. Iran J Pharm Res Spring 18:877-886.
12. Safayhi H et al. (1992) Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261: 1143 - 1146.
13. Safayhi H et al. (1997) Inhibition by boswellic acids of human leukocyte elastase. J. Pharmacol Exp Ther 28: 1460 - 463.
14. Sander O et al. (1998) Is H15 (resin extract of Boswellia serrata incense) a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol 57: 11 - 16.
15. Wang L-G et al. (1991) Determination of DNA topoisomerase II activity from L1210 cells - a target for screening antitumor agents. Acta Pharmacol Sinica 12: 108 - 114.
16. Warnke et al. (1998): The role of boswellic acids in the therapy of malignant gliomas: methodological shortcomings. German Medical Journal 95: 220
17. https://arzneipflanzenlexikon.info/weihrauch.php
18. https://www.awl.ch/heilpflanzen/boswellia_sacra/weihrauch.htm